Medinol is currently running NIRTRAKS, a post marketing study of the NIRxcell stent in the United States. NIRxcell is Medinol's fifth generation coronary stent and has demonstrated outstanding clinical results with an exceptionally low TLR rate.

 

Accordion Title: 
NIRxcell Clinical Data
eDES Trials
Icon: 
class="block__title block-title">Download file

© 2015 Medinol Ltd · MKW2016-0